Geron GERN Research and clinical expenses — R&D

Similar metrics at other companies

MPLTClinical Trial — Research And Development Expense

$24.82M+1,180%

DBVTExpenses by function — Research and development expense

$8.5M+84.8%

NRIXInternal research and development expenses — R&D

$57.07M+12.2%

BCRXResearch, discovery and preclinical programs — Research and Development Expense (Excluding Acquired in Process Cost)

$3.97M+30.4%

ZYMEExpense for other preclinical and research programs — R&D

$7.26M+19.6%

MPLTPreclinical Program — Research And Development Expense

$5.52M-9.2%

Questions, answered.

What is Geron's research and clinical expenses — R&D?

Geron (GERN) reported research and clinical expenses — R&D of $13M in Q1 2026.

How has Geron's research and clinical expenses — R&D changed year-over-year?

Geron's research and clinical expenses — R&D decreased by 5.1% year-over-year, from $13.7M to $13M.

What does research and clinical expenses — R&D mean?

This metric represents the aggregate costs incurred by the company to support the advancement of its clinical-stage drug pipeline, including laboratory research, clinical trial execution, and regulatory development activities. It reflects the capital intensity of the company's core innovation efforts and its commitment to moving therapeutic candidates through the drug development lifecycle. Monitoring these expenses provides insight into the company's investment strategy for future product commercialization and its overall operational burn rate.